Genetic investigation in patients with histological variants of bladder cancer: clinical implications.

IF 2.8 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2025-08-25 DOI:10.1080/14737140.2025.2548487

Nikoo Emtiazi, Ehsan Zolfi, Farhood Khaleghi Mehr

{"title":"Genetic investigation in patients with histological variants of bladder cancer: clinical implications.","authors":"Nikoo Emtiazi, Ehsan Zolfi, Farhood Khaleghi Mehr","doi":"10.1080/14737140.2025.2548487","DOIUrl":null,"url":null,"abstract":"Introduction: Understanding histological variants is crucial for accurate diagnosis and management of bladder cancer (BC). Most BCs are urothelial carcinomas (UC), which can evolve into aggressive histological variants (HVs) such as micropapillary, plasmacytoid, small-cell carcinoma, and sarcomatoid subtypes.Areas covered: This review will focus on the clinicopathologic characteristics of the most common non-urothelial and other rare variants (signet-ring cell variant, decoy cells, osteoclastic giant cell variant) BCs, to be distinguished from BC variant histology containing a UC component. In addition, we reviewed the effects of understanding HVs in developing therapeutic and diagnostic methods for BC. Our analysis combines evidence from searches in PubMed/NCBI, Google Scholar, ClinicalTrials.gov, and key conference proceedings from 2011 to 2025.Expert opinion: Recognizing and differentiating between various variant histology (VH) subtypes is crucial for tailoring treatment strategies and improving patient outcomes. Discovering and uniform reporting of variant histology in UC is essential. Clinical trials focusing specifically on patients with HVs are needed to evaluate the impact of new treatment modalities and optimize management strategies. More clinical studies with specific guidelines and goals, along with research, patient records, databases, and tissue banks, are needed to improve treatment plans and identify markers for patients with urinary tract cancer.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-23"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2548487","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Understanding histological variants is crucial for accurate diagnosis and management of bladder cancer (BC). Most BCs are urothelial carcinomas (UC), which can evolve into aggressive histological variants (HVs) such as micropapillary, plasmacytoid, small-cell carcinoma, and sarcomatoid subtypes.

Areas covered: This review will focus on the clinicopathologic characteristics of the most common non-urothelial and other rare variants (signet-ring cell variant, decoy cells, osteoclastic giant cell variant) BCs, to be distinguished from BC variant histology containing a UC component. In addition, we reviewed the effects of understanding HVs in developing therapeutic and diagnostic methods for BC. Our analysis combines evidence from searches in PubMed/NCBI, Google Scholar, ClinicalTrials.gov, and key conference proceedings from 2011 to 2025.

Expert opinion: Recognizing and differentiating between various variant histology (VH) subtypes is crucial for tailoring treatment strategies and improving patient outcomes. Discovering and uniform reporting of variant histology in UC is essential. Clinical trials focusing specifically on patients with HVs are needed to evaluate the impact of new treatment modalities and optimize management strategies. More clinical studies with specific guidelines and goals, along with research, patient records, databases, and tissue banks, are needed to improve treatment plans and identify markers for patients with urinary tract cancer.

查看原文本刊更多论文

膀胱癌组织学变异患者的遗传学研究：临床意义。

了解组织学变异对膀胱癌（BC）的准确诊断和治疗至关重要。大多数bc为尿路上皮癌（UC），可演变为侵袭性组织学变异（HVs），如微乳头状癌、浆细胞样癌、小细胞癌和肉瘤样亚型。涵盖领域：本综述将重点关注最常见的非尿路上皮和其他罕见变异（印戒细胞变异、诱骗细胞、破骨巨细胞变异）BC的临床病理特征，以区别于含有UC成分的BC变异组织学。此外，我们回顾了了解hiv在开发BC治疗和诊断方法中的作用。我们的分析结合了PubMed/NCBI、b谷歌Scholar、ClinicalTrials.gov和2011年至2025年重要会议记录的搜索证据。专家意见：识别和区分各种变异组织学（VH）亚型对于定制治疗策略和改善患者预后至关重要。发现和统一报告UC的变异组织学是必要的。需要专门针对hiv患者的临床试验来评估新治疗方式的影响并优化管理策略。需要更多具有具体指导方针和目标的临床研究，以及研究、患者记录、数据库和组织库，以改进治疗计划并确定尿路癌患者的标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.